Pipeline

We are focused on the treatment of hemophilia using our high potency coagulation factors that promote blood clotting. A clinical trial of our Factor IX candidate in individuals with hemophilia B was initiated in June of 2017. We also plan to initiate an efficacy clinical trial of our Factor VIIa candidate in individuals with hemophilia and inhibitors in the fourth quarter of 2017.

Next Generation Hemostasis Programs

Hemophilia A or B with Inhibitors
Phase 2/3
    
Drug Candidate
Indication
Research
Preclinical
Phase 1/2
Phase 2/3

*(formerly known as CB 813d)

Anti-Complement Program Available for Partnering